TB CAB

Webinar: Implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB

Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB) and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) will host a webinar on 16 August 2018 at 10 am EDT / 4 pm South Africa / 5 pm Kenya on implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB (DR-TB) in light of the new World Health Organization (WHO) policy brief on DR-TB regimens.

Read More →

Global TB CAB responds to new bedaquiline price

The TB CAB reiterates its request for Johnson & Johnson to commit to a global price for bedaquiline that is no higher than US$32 per month.

Read More →

Webinar: Implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB

Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB) and DR-TB STAT will host a webinar on 1 August 2018 at 10 am New York / 4pm South Africa / 5pm Kenya on implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB.

Read More →

Activists call on Johnson & Johnson to drop the price of bedaquiline

Activists ask the company to drop the price of bedaquiline in all markets to $32 a month or lower.

Read More →

South Africa makes bedaquiline part of its standard recommended treatment regimen for rifampicin-resistant TB

Global TB CAB welcomes introduction of safer drug for most South Africans with rifampicin-resistant TB; Other countries and the World Health Organization must now follow.

Read More →

Advocates call for urgent reforms of WHO TB diagnosis and treatment guidelines

Advocates call on WHO leadership to ensure rapid development of clear, consolidated guidelines for the diagnosis and treatment of TB.

Read More →

Advocates call on WHO to consolidate and revise its guidance regarding the treatment for MDR-TB

TB CAB issues a position statement on the use of bedaquiline as part of the preferred regimen for MDR-TB.

Read More →

TB CAB's proposed development pathway for regimens to treat XDR-TB

Тhe Global TB Community Advisory Board (TB CAB) releases a position paper regarding the optimal design for future evaluation of regimens for the treatment of extensively drug-resistant TB (XDR-TB).

Read More →

Advocates call on Kenyan DLTLD to adopt new TB test

TB advocates urge the Kenyan Division of Leprosy, Tuberculosis and Lung Disease (DLTLD) to introduce a new, simple, and rapid TB test, TB LAM, which detects TB antigens in urine, and is an important tool for detecting TB in certain populations living with HIV.

Read More →

Advocates encourage the health authorities in Peru to approve the endTB study

TB advocates stress the importance of the observational endTB study for expanding access to new treatments for multidrug-resistant TB in Peru.

Read More →

Page 2 of 6 · Total posts: 10

←First 1 2 3 Last→